Discuss MannKind Corp.
MannKind Corp.
WKN: A2DMZL / Symbol: MNKD / Name: MannKind / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
4,94 €
0,02 %
MannKind Corporation (NASDAQ: MNKD) had its price target lowered by analysts at Royal Bank Of Canada from $10.00 to $8.00. They now have an "outperform" rating on the stock.
Ratings data for MNKD provided by MarketBeat
MannKind Corporation (NASDAQ: MNKD) had its price target lowered by analysts at Royal Bank Of Canada from $8.00 to $7.00. They now have an "outperform" rating on the stock.
Ratings data for MNKD provided by MarketBeat
MannKind (NASDAQ:MNKD) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Ratings data for MNKD provided by MarketBeat
MannKind (NASDAQ:MNKD) had its price target raised by analysts at Royal Bank Of Canada from $7.00 to $8.00. They now have an "outperform" rating on the stock.
Ratings data for MNKD provided by MarketBeat
MannKind (NASDAQ:MNKD) had its price target raised by analysts at HC Wainwright from $9.00 to $11.00. They now have a "buy" rating on the stock.
Ratings data for MNKD provided by MarketBeat
MannKind (NASDAQ:MNKD) had its price target raised by analysts at Wells Fargo & Company from $9.00 to $10.00. They now have an "overweight" rating on the stock.
Ratings data for MNKD provided by MarketBeat
MannKind (NASDAQ:MNKD) had its price target raised by analysts at Oppenheimer Holdings, Inc. from $12.00 to $15.00. They now have an "outperform" rating on the stock.
Ratings data for MNKD provided by MarketBeat
MannKind (NASDAQ:MNKD) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
Ratings data for MNKD provided by MarketBeat
MannKind (NASDAQ:MNKD) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $9.00 price target on the stock.
Ratings data for MNKD provided by MarketBeat
MannKind (NASDAQ:MNKD) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
Ratings data for MNKD provided by MarketBeat
MannKind (NASDAQ:MNKD) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $10.00 price target on the stock.
Ratings data for MNKD provided by MarketBeat
MannKind (NASDAQ:MNKD) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Ratings data for MNKD provided by MarketBeat
MannKind (NASDAQ:MNKD) had its price target lowered by analysts at Wells Fargo & Company from $10.00 to $8.00. They now have an "overweight" rating on the stock.
Ratings data for MNKD provided by MarketBeat
MannKind (NASDAQ:MNKD) had its price target lowered by analysts at Royal Bank Of Canada from $8.00 to $7.50. They now have an "outperform" rating on the stock.
Ratings data for MNKD provided by MarketBeat
MannKind (NASDAQ:MNKD) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $7.00 price target on the stock.
Ratings data for MNKD provided by MarketBeat
MannKind (NASDAQ:MNKD) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
Ratings data for MNKD provided by MarketBeat
Neueste Beiträge
Cowen_Inc in Rhythm Pharmaceuticals diskutieren